MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Bristol-Myers Squibb Co.

Fechado

SetorSaúde

59.58 0.18

Visão Geral

Variação de preço das ações

24h

Atual

Mín

59.11

Máximo

60.13

Indicadores-chave

By Trading Economics

Rendimento

-1.1B

76M

Vendas

442M

12B

P/E

Médio do Setor

14.05

63.778

EPS

1.67

Rendimento de Dividendos

4.07

Margem de lucro

0.616

Funcionários

34,100

EBITDA

-1.9B

2.6B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+2.32% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.07%

2.39%

Próximos Ganhos

24 de abr. de 2025

Próxima data de dividendos

1 de mai. de 2025

Próxima data de ex-dividendo

4 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

311M

121B

Abertura anterior

59.4

Fecho anterior

59.58

Sentimento de Notícias

By Acuity

37%

63%

130 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Bristol-Myers Squibb Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mar. de 2025, 10:13 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 de mar. de 2025, 10:13 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6 de fev. de 2025, 12:13 UTC

Ganhos

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11 de mar. de 2025, 02:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11 de mar. de 2025, 02:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11 de mar. de 2025, 02:26 UTC

Aquisições, Fusões, Aquisições de Empresas

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11 de mar. de 2025, 02:23 UTC

Aquisições, Fusões, Aquisições de Empresas

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11 de mar. de 2025, 02:22 UTC

Aquisições, Fusões, Aquisições de Empresas

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11 de mar. de 2025, 02:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11 de mar. de 2025, 02:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11 de mar. de 2025, 02:19 UTC

Aquisições, Fusões, Aquisições de Empresas

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 de fev. de 2025, 15:35 UTC

Ganhos

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6 de fev. de 2025, 13:56 UTC

Ganhos

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6 de fev. de 2025, 13:25 UTC

Principais Notícias
Ganhos

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 de fev. de 2025, 12:00 UTC

Ganhos

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol-Myers Squibb 4Q Net $72M >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol-Myers Squibb 4Q EPS 4c >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6 de fev. de 2025, 11:59 UTC

Ganhos

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Comparação entre Pares

Variação de preço

Bristol-Myers Squibb Co. Previsão

Preço-alvo

By TipRanks

2.32% parte superior

Previsão para 12 meses

Média 60.93 USD  2.32%

Máximo 70 USD

Mínimo 37 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

16 ratings

5

Comprar

10

Manter

1

Vender

Pontuação Técnica

By Trading Central

59.18 / 59.9Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

130 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.